Prof. Dr. med. Pietro Vernazza
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA : the journal of the American Medical Association 1999; 282:2220-6.
15.12.1999AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study
15.12.1999JAMA : the journal of the American Medical Association 1999; 282:2220-6
Ledergerber B, Francioli P, Sudre P, Kaufmann D, Opravil M, Bernasconi E, Vernazza Pietro, Battegay M, Furrer H, Hirschel B, Weber R, Erard V, Egger M, Telenti A
HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
Wendland T, Furrer H, Vernazza P, Frutig K, Christen A, Matter L, Malinverni R, Pichler W. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS (London, England) 1999; 13:1857-62.
01.10.1999HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
01.10.1999AIDS (London, England) 1999; 13:1857-62
Wendland T, Furrer H, Vernazza Pietro, Frutig K, Christen A, Matter L, Malinverni R, Pichler W J
Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
Zinkernagel C, Ledergerber B, Battegay M, Cone R, Vernazza P, Hirschel B, Opravil M. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study. AIDS (London, England) 1999; 13:1587-9.
20.08.1999Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
20.08.1999AIDS (London, England) 1999; 13:1587-9
Zinkernagel C, Ledergerber B, Battegay M, Cone R W, Vernazza Pietro, Hirschel B, Opravil M
Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study
Schlegel M, Osterwalder J, Galeazzi R, Vernazza P. Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study. BMJ (Clinical research ed.) 1999; 319:352.
07.08.1999Comparative efficacy of three mumps vaccines during disease outbreak in Eastern Switzerland: cohort study
07.08.1999BMJ (Clinical research ed.) 1999; 319:352
Schlegel Matthias, Osterwalder Joseph, Galeazzi R L, Vernazza Pietro
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
Bassetti S, Bernasconi E, Vernazza P, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9.
01.06.1999Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study
01.06.1999Journal of acquired immune deficiency syndromes (1999) 1999; 21:114-9
Bassetti S, Bernasconi E, Vernazza Pietro, Telenti A, Kaiser L, Flepp M, Rickenbach M, Furrer H, Battegay M, Sudre P
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
Furrer H, Flepp M, Rickenbach M, Vernazza P, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. The New England journal of medicine 1999; 340:1301-6.
29.04.1999Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
29.04.1999The New England journal of medicine 1999; 340:1301-6
Furrer H, Flepp M, Rickenbach M, Vernazza Pietro, Telenti A, Battegay M, Hirschel B, Bernasconi E, Opravil M, Egger M, Malinverni R
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza P, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-8.
13.03.1999Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
13.03.1999Lancet 1999; 353:863-8
Ledergerber B, Francioli P, Furrer H, Flepp M, Sudre P, Vernazza Pietro, Battegay M, Hirschel B, Telenti A, Opravil M, Egger M, Weber R
Sexual transmission of HIV: infectiousness and prevention
Vernazza P, Eron J, Fiscus S, Cohen M. Sexual transmission of HIV: infectiousness and prevention. AIDS (London, England) 1999; 13:155-66.
04.02.1999Sexual transmission of HIV: infectiousness and prevention
04.02.1999AIDS (London, England) 1999; 13:155-66
Vernazza Pietro, Eron J J, Fiscus S A, Cohen M S
[HIV 1998: eradication dreams?]
Vernazza P. [HIV 1998: eradication dreams?]. Schweizerische medizinische Wochenschrift 1998; 128:2019-22.
26.12.1998[HIV 1998: eradication dreams?]
26.12.1998Schweizerische medizinische Wochenschrift 1998; 128:2019-22
Vernazza Pietro
Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
Bisset L, Cone R, Huber W, Battegay M, Vernazza P, Weber R, Grob P, Opravil M. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:2115-23.
12.11.1998Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study
12.11.1998AIDS (London, England) 1998; 12:2115-23
Bisset L R, Cone R W, Huber W, Battegay M, Vernazza Pietro, Weber R, Grob P J, Opravil M
Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission
Eron J, Vernazza P, Johnston D, Seillier-Moiseiwitsch F, Alcorn T, Fiscus S, Cohen M. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS (London, England) 1998; 12:F181-9.
22.10.1998Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission
22.10.1998AIDS (London, England) 1998; 12:F181-9
Eron J J, Vernazza Pietro, Johnston D M, Seillier-Moiseiwitsch F, Alcorn T M, Fiscus S A, Cohen M S
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
Rutschmann O, Perrin L, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS (London, England) 1998; 12:F71-7.
28.05.1998A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
28.05.1998AIDS (London, England) 1998; 12:F71-7
Rutschmann O T, Perrin L H, Yerly S, Leduc D, Sudre P, Bernasconi E, Bucher H C, Vernazza Pietro, Malinverni R, Iten A, Opravil M, Hirschel B
[Sexual transmission of HIV: effect of potent antiretroviral therapy]
Vernazza P. [Sexual transmission of HIV: effect of potent antiretroviral therapy]. Therapeutische Umschau. Revue thérapeutique 1998; 55:285-8.
01.05.1998[Sexual transmission of HIV: effect of potent antiretroviral therapy]
01.05.1998Therapeutische Umschau. Revue thérapeutique 1998; 55:285-8
Vernazza Pietro
Factors associated with changes in HIV shedding in semen
Fiscus S, Vernazza P, Gilliam B, Dyer J, Eron J, Cohen M. Factors associated with changes in HIV shedding in semen. AIDS research and human retroviruses 1998; 14 Suppl 1:S27-31.
01.04.1998Factors associated with changes in HIV shedding in semen
01.04.1998AIDS research and human retroviruses 1998; 14 Suppl 1:S27-31
Fiscus S A, Vernazza Pietro, Gilliam B, Dyer J, Eron J J, Cohen M S
Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi
Dyer J, Eron J, Hoffman I, Kazembe P, Vernazza P, Nkata E, Costello Daly C, Fiscus S, Cohen M. Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. The Journal of infectious diseases 1998; 177:224-7.
01.01.1998Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi
01.01.1998The Journal of infectious diseases 1998; 177:224-7
Dyer J R, Eron J J, Hoffman I F, Kazembe P, Vernazza Pietro, Nkata E, Costello Daly C, Fiscus S A, Cohen M S
Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study
Rutschmann O, Yerly S, Perrin L, Bernasconi E, Bucher H, Vernazza P, Malinverni R, Iten A, Opravil M, Hirschel B. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study. Antiviral therapy 1998; 3 Suppl 4:65-7.
01.01.1998Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study
01.01.1998Antiviral therapy 1998; 3 Suppl 4:65-7
Rutschmann O T, Yerly S, Perrin L H, Bernasconi E, Bucher H, Vernazza Pietro, Malinverni R, Iten A, Opravil M, Hirschel B
[HIV: "big bang" in view]
Vernazza P. [HIV: "big bang" in view]. Schweizerische medizinische Wochenschrift 1997; 127:2129-31.
27.12.1997[HIV: "big bang" in view]
27.12.1997Schweizerische medizinische Wochenschrift 1997; 127:2129-31
Vernazza Pietro
Condom semen samples for unlinked anonymous HIV testing
Vernazza P, Gresser S, Koller C, Osterwalder J. Condom semen samples for unlinked anonymous HIV testing. Lancet 1995; 346:962-3.
07.10.1995Condom semen samples for unlinked anonymous HIV testing
07.10.1995Lancet 1995; 346:962-3
Vernazza Pietro, Gresser S, Koller C, Osterwalder Joseph
[Cerebral toxoplasmosis with central diabetes insipidus and panhypopituitarism in a patient with AIDS]
Brändle M, Vernazza P, Oesterle M, Galeazzi R. [Cerebral toxoplasmosis with central diabetes insipidus and panhypopituitarism in a patient with AIDS]. Schweizerische medizinische Wochenschrift 1995; 125:684-7.
08.04.1995[Cerebral toxoplasmosis with central diabetes insipidus and panhypopituitarism in a patient with AIDS]
08.04.1995Schweizerische medizinische Wochenschrift 1995; 125:684-7
Brändle Michael, Vernazza Pietro, Oesterle M, Galeazzi R L